Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | GRM8 | O00222 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 2/20 | 0.35 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1724939 | 0.89 | PDE10A (0.41) | PDE2APDE10AGRM8CYP1A2GRM7 | |
| SCHEMBL1727361 | 0.88 | CYP1A2 (0.32) | PDE2APDE10ACYP1A2 | |
| SCHEMBL173553 | 0.78 | PDE2A (0.47) | PDE2APDE10AGRM8CYP1A2GRM7 | |
| SCHEMBL173584 | 0.73 | PDE10A (0.47) | PDE2APDE10AGRM8CYP1A2GRM7 | |
| SCHEMBL170955 | 0.72 | POLB (0.35) | CYP1A2POLB | |
| SCHEMBL1725765 | 0.71 | CHEK1 (0.42) | CYP1A2PKMPOLBLMNA | |
| SCHEMBL20698176 | 0.69 | PDE2A (0.55) | PDE2APDE10AGRM8CYP1A2GRM7 | |
| SCHEMBL20698000 | 0.67 | PDE2A (0.40) | PDE2APDE10AGRM8CYP1A2GRM7 | |
| SCHEMBL1725979 | 0.66 | CHEK1 (0.38) | CYP1A2POLBLMNA | |
| SCHEMBL20697961 | 0.66 | PDE2A (0.44) | PDE2APDE10AGRM8CYP1A2GRM7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10448639-B2 | Fungicidal pyrazoles | FMC CORPORATION (US) | 2019-10-22 | — | — | US | disclosed |
| US-20170223959-A1 | FUNGICIDAL PYRAZOLES | FMC CORPORATION | 2017-08-10 | — | — | US | disclosed |
| US-9655361-B2 | Fungicidal pyrazoles | E I DU PONT DE NEMOURS AND COMPANY (US) | 2017-05-23 | — | — | US | disclosed |
| EP-2403834-B1 | FUNGICIDAL PYRAZOLES | DU PONT (US) | 2015-12-02 | — | — | EP | disclosed |
| US-20150230467-A1 | FUNGICIDAL PYRAZOLES | FMC CORPORATION | 2015-08-20 | — | — | US | disclosed |
| US-9062005-B2 | Fungicidal pyrazoles | E I DU PONT DE NEMOURS AND COMPANY (US) | 2015-06-23 | — | — | US | disclosed |
| EP-2403834-A1 | Fungicidal pyrazoles | E. I. du Pont de Nemours and Company (US) | 2012-01-11 | — | — | EP | disclosed |
| US-20110319430-A1 | FUNGICIDAL PYRAZOLES | E.I. DU PONT NEMOURS AND COMPANY (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2010101973-A1 | FUNGICIDAL PYRAZOLES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319430-A1 | FUNGICIDAL PYRAZOLES | CBR3, CBR1, CYP2S1 | PDE2A 2527/4885PDE10A 3393/4885GRM8 2110/4885 |
| US-10448639-B2 | Fungicidal pyrazoles | CBR3, CBR1, CYP2S1 | PDE2A 2527/4885PDE10A 3393/4885GRM8 2110/4885 |
| US-20150230467-A1 | FUNGICIDAL PYRAZOLES | CBR3, CBR1, CYP2S1 | PDE2A 2527/4885PDE10A 3393/4885GRM8 2110/4885 |
| US-20170223959-A1 | FUNGICIDAL PYRAZOLES | CBR3, CBR1, CYP2S1 | PDE2A 2527/4885PDE10A 3393/4885GRM8 2110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.